Hepatic Venous Outflow Obstruction

Part of the Molecular Pathology Library book series (MPLB, volume 5)


The liver is the largest organ in the body and its dual blood supply makes it a unique organ. Although it makes up less than 3% of total body weight (about 1,800 g in men and 1,400 g in women), the liver receives one-quarter of the total cardiac output via the hepatic artery and portal vein [1]. Classically, the liver has been divided in to two lobes, right and left lobe. For more details on liver anatomy, please see Chap. 1. However, today the terms “left” and “right” liver has been used on the basis of the distribution of vessels and ducts by a line extending between the inferior vena cava (IVC) and gallbladder. Furthermore, the liver can be divided into eight segments. The left liver is composed of a classical left lobe and a caudate lobe. The portal vein carries blood from the digestive tract (proximal stomach, upper rectum, and pancreas), spleen and gallbladder. Many portal vein anomalies have been reported, either congenital or as a result of neonatal omphalitis or portal vein thrombosis, in which nodular hyperplasia or left lobe atrophy occur because of remodeling of the liver.


Inferior Vena Cava Hematopoietic Stem Cell Transplantation Hepatic Vein Caudate Lobe Constrictive Pericarditis 


  1. 1.
    Lautt WW, Greenway CV. Conceptual review of the hepatic vascular bed. Hepatology. 1987;7:952–63.PubMedGoogle Scholar
  2. 2.
    Rosenberg PM, Friedman LS. The liver in circulatory failure. In: Schiff ER SM, Maddrey WC, editors. Schiff’s diseases of the liver. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1327–140.Google Scholar
  3. 3.
    Shulman HM, McDonald GB, Matthews D, et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology. 1980;79:1178–91.PubMedGoogle Scholar
  4. 4.
    Moussavian SN, Dincsoy HP, Goodman S, Helm RA, Bozian RC. Severe hyperbilirubinemia and coma in chronic congestive heart failure. Dig Dis Sci. 1982;27:175–80.PubMedGoogle Scholar
  5. 5.
    Nouel O, Henrion J, Bernuau J, Degott C, Rueff B, Benhamou JP. Fulminant hepatic failure due to transient circulatory failure in patients with chronic heart disease. Dig Dis Sci. 1980;25:49–52.PubMedGoogle Scholar
  6. 6.
    Kisloff B, Schaffer G. Fulminant hepatic failure secondary to congestive heart failure. Am J Dig Dis. 1976;21:895–900.PubMedGoogle Scholar
  7. 7.
    Richman SM, Delman AJ, Grob D. Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes. Am J Med. 1961;30:211–25.PubMedGoogle Scholar
  8. 8.
    Jafri SM, Mammen EF, Masura J, Goldstein S. Effects of warfarin on markers of hypercoagulability in patients with heart failure. Am Heart J. 1997;134:27–36.PubMedGoogle Scholar
  9. 9.
    Bessman AN, Evans JM. The blood ammonia in congestive heart failure. Am Heart J. 1955;50:715–9.PubMedGoogle Scholar
  10. 10.
    Arora A, Seth S, Sharma MP, Acharya SK, Mukhopadhayaya S. Case report: unusual CT appearances in a case of Budd-Chiari syndrome. Clin Radiol. 1991;43:431–2.PubMedGoogle Scholar
  11. 11.
    Solano Jr FX, Young E, Talamo TS, Dekker A. Constrictive pericarditis mimicking Budd-Chiari syndrome. Am J Med. 1986;80:113–5.PubMedGoogle Scholar
  12. 12.
    Ling LH, Oh JK, Schaff HV, et al. Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation. 1999;100:1380–6.PubMedGoogle Scholar
  13. 13.
    Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation. 2003;108:1146–62.PubMedGoogle Scholar
  14. 14.
    Talreja DR, Edwards WD, Danielson GK, et al. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation. 2003;108:1852–7.PubMedGoogle Scholar
  15. 15.
    Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet. 2004;363:717–27.PubMedGoogle Scholar
  16. 16.
    Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol. 1995;22:1–9.PubMedGoogle Scholar
  17. 17.
    Valla D. Hepatic venous outflow tract obstruction etipathogenesis: Asia versus the West. J Gastroenterol Hepatol. 2004;19:S204–11.Google Scholar
  18. 18.
    Shrestha SM, Okuda K, Uchida T, et al. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol. 1996;11:170–9.PubMedGoogle Scholar
  19. 19.
    Darwish Murad S, Plessier A, Hernandez-Guerra M, Primignani M, Elias E, Bahr M. A prospective follow-up study on 163 patients with Budd-Chiari syndrome: results from the european network for vascular disorders of the Liver (EN-Vie). J Hepatol. 2007;46:S4.Google Scholar
  20. 20.
    Bayraktar Y, Balkanci F, Kansu E, et al. Budd-Chiari syndrome: analysis of 30 cases. Angiology. 1993;44:541–51.PubMedGoogle Scholar
  21. 21.
    Bogin V, Marcos A, Shaw-Stiffel T. Budd-Chiari syndrome: in evolution. Eur J Gastroenterol Hepatol. 2005;17:33–5.PubMedGoogle Scholar
  22. 22.
    Karadag O, Akinci D, Aksoy DY, Bayraktar Y. Acute Budd-Chiari syndrome resulting from a pyogenic liver abscess. Hepatogastroenterology. 2005;52:1554–6.PubMedGoogle Scholar
  23. 23.
    Valla DC. Hepatic vein thrombosis (Budd-Chiari syndrome). Semin Liver Dis. 2002;22:5–14.PubMedGoogle Scholar
  24. 24.
    Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–8.PubMedGoogle Scholar
  25. 25.
    Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology Lancet. 1996;348:573–7.Google Scholar
  26. 26.
    Deltenre P, Denninger MH, Hillaire S, et al. Factor V Leiden related Budd-Chiari syndrome. Gut. 2001;48:264–8.PubMedGoogle Scholar
  27. 27.
    Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut. 1997;40:798–800.PubMedGoogle Scholar
  28. 28.
    Valla DC. The diagnosis and management of the Budd-Chiari ­syndrome: consensus and controversies. Hepatology. 2003;38:793–803.PubMedGoogle Scholar
  29. 29.
    Simson IW. Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in South Africa. Gastroenterology. 1982;82:171–8.PubMedGoogle Scholar
  30. 30.
    Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Behcet’s disease. Am J Gastroenterol. 1997;92:858–62.PubMedGoogle Scholar
  31. 31.
    Bayraktar Y, Egesel T, Saglam F, Balkanci F, Van Thiel DH. Does hepatic vein outflow obstruction contribute to the pathogenesis of hepatocellular carcinoma? J Clin Gastroenterol. 1998;27:67–71.PubMedGoogle Scholar
  32. 32.
    Moucari R, Rautou PE, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut. 2008;57:828–35.PubMedGoogle Scholar
  33. 33.
    James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.PubMedGoogle Scholar
  34. 34.
    Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922–9.PubMedGoogle Scholar
  35. 35.
    Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528–34.PubMedGoogle Scholar
  36. 36.
    De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5:708–14.PubMedGoogle Scholar
  37. 37.
    Regina S, Herault O, D’Alteroche L, Binet C, Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost. 2007;5:859–61.PubMedGoogle Scholar
  38. 38.
    Colaizzo D, Amitrano L, Iannaccone L, et al. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet. 2007;44:412–6.PubMedGoogle Scholar
  39. 39.
    Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130:2031–8.PubMedGoogle Scholar
  40. 40.
    Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis. 2002;22:15–26.PubMedGoogle Scholar
  41. 41.
    Valla D, Hadengue A, el Younsi M, et al. Hepatic venous outflow block caused by short-length hepatic vein stenoses. Hepatology. 1997;25:814–9.PubMedGoogle Scholar
  42. 42.
    Cazals-Hatem D, Vilgrain V, Genin P, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology. 2003;37:510–9.PubMedGoogle Scholar
  43. 43.
    Darwish Murad S, Valla DC, de Groen PC, et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol. 2006;101:83–90.PubMedGoogle Scholar
  44. 44.
    Paradis V, Bieche I, Dargere D, et al. Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease. Gut. 2005;54:1776–81.PubMedGoogle Scholar
  45. 45.
    Sherlock S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J. 1951;13:273–93.PubMedGoogle Scholar
  46. 46.
    Henrion J. Ischemia/reperfusion injury of the liver: pathophysiologic hypotheses and potential relevance to human hypoxic hepatitis. Acta Gastroenterol Belg. 2000;63:336–47.PubMedGoogle Scholar
  47. 47.
    Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2, 500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11:787–97.PubMedGoogle Scholar
  48. 48.
    Hadengue A, Poliquin M, Vilgrain V, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology. 1994;106:1042–7.PubMedGoogle Scholar
  49. 49.
    Parker RG. Occlusion of the hepatic veins in man. Medicine (Baltimore). 1959;38:369–402.Google Scholar
  50. 50.
    Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore). 1994;73:21–36.Google Scholar
  51. 51.
    Darwish Murad S, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004;39:500–8.PubMedGoogle Scholar
  52. 52.
    De BK, Sen S, Biswas PK, et al. Occurrence of hepatopulmonary syndrome in Budd-Chiari syndrome and the role of venous decompression. Gastroenterology. 2002;122:897–903.PubMedGoogle Scholar
  53. 53.
    Singh V, Sinha SK, Nain CK, et al. Budd-Chiari syndrome: our experience of 71 patients. J Gastroenterol Hepatol. 2000;15:550–4.PubMedGoogle Scholar
  54. 54.
    Kage M, Arakawa M, Kojiro M, Okuda K. Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology. 1992;102:2081–90.PubMedGoogle Scholar
  55. 55.
    Bayraktar Y, Balkanci F, Kansu E, Dundar S, Telatar H. Portal hypertension in Behcet syndrome. AJR Am J Roentgenol. 1989;152:1342.PubMedGoogle Scholar
  56. 56.
    Bayraktar Y, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol. 2006;12:1165–74.PubMedGoogle Scholar
  57. 57.
    Yoshimoto K, Ono N, Okamura T, Sata M. Recent progress in the diagnosis and therapy for veno-occlusive disease of the liver. Leuk Lymphoma. 2003;44:229–34.PubMedGoogle Scholar
  58. 58.
    Valla DC. Primary Budd-Chiari syndrome. J Hepatol. 2009;­50:195–203.PubMedGoogle Scholar
  59. 59.
    Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology. 1999;30:84–9.PubMedGoogle Scholar
  60. 60.
    Tang TJ, Batts KP, de Groen PC, et al. The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. J Hepatol. 2001;35:338–43.PubMedGoogle Scholar
  61. 61.
    Henderson JM, Warren WD, Millikan Jr WJ, et al. Surgical options, hematologic evaluation, and pathologic changes in Budd-Chiari syndrome. Am J Surg. 1990;159:41–8. discussion 8–50.PubMedGoogle Scholar
  62. 62.
    Faust TW. Budd-Chiari syndrome. Curr Treat Options Gastroenterol. 1999;2:491–504.PubMedGoogle Scholar
  63. 63.
    Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38:364–71.PubMedGoogle Scholar
  64. 64.
    Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology. 2006;44:1308–16.PubMedGoogle Scholar
  65. 65.
    de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of ­diagnosis and therapy in portal hypertension. J Hepatol. 2005;43:167–76.PubMedGoogle Scholar
  66. 66.
    Primignani M, Dell’Era A, Fabris FM, Reati R, Artoni A, Mannucci PM. High incidence of heparin-induced thrombocythemia (HIT) in splanchnic vein thrombosis treated with low molecular weight heparin 5LMWH. J Hepatol. 2008;48:S113.Google Scholar
  67. 67.
    Wadhawan M, Kumar N. Budd-Chiari syndrome. Trop Gastroenterol. 2003;24:3–7.PubMedGoogle Scholar
  68. 68.
    Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med. 2004;350:578–85.PubMedGoogle Scholar
  69. 69.
    Frank JW, Kamath PS, Stanson AW. Budd-Chiari syndrome: early intervention with angioplasty and thrombolytic therapy. Mayo Clin Proc. 1994;69:877–81.PubMedGoogle Scholar
  70. 70.
    Raju GS, Felver M, Olin JW, Satti SD. Thrombolysis for acute Budd-Chiari syndrome: case report and literature review. Am J Gastroenterol. 1996;91:1262–3.PubMedGoogle Scholar
  71. 71.
    Sparano J, Chang J, Trasi S, Bonanno C. Treatment of the Budd-Chiari syndrome with percutaneous transluminal angioplasty. Case report and review of the literature. Am J Med. 1987;82:821–8.PubMedGoogle Scholar
  72. 72.
    Xu K, He FX, Zhang HG, et al. Budd-Chiari syndrome caused by obstruction of the hepatic inferior vena cava: immediate and 2-year treatment results of transluminal angioplasty and metallic stent placement. Cardiovasc Intervent Radiol. 1996;19:32–6.PubMedGoogle Scholar
  73. 73.
    Zhang CQ, Fu LN, Xu L, et al. Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome. World J Gastroenterol. 2003;9:2587–91.PubMedGoogle Scholar
  74. 74.
    Pisani-Ceretti A, Intra M, Prestipino F, et al. Surgical and radiologic treatment of primary Budd-Chiari syndrome. World J Surg. 1998;22:48–53. discussion 4.PubMedGoogle Scholar
  75. 75.
    Witte AM, Kool LJ, Veenendaal R, Lamers CB, van Hoek B. Hepatic vein stenting for Budd-Chiari syndrome. Am J Gastroenterol. 1997;92:498–501.PubMedGoogle Scholar
  76. 76.
    Ryu RK, Durham JD, Krysl J, et al. Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. J Vasc Interv Radiol. 1999;10:799–805.PubMedGoogle Scholar
  77. 77.
    Ganger DR, Klapman JB, McDonald V, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis: review of indications and problems. Am J Gastroenterol. 1999;94:603–8.PubMedGoogle Scholar
  78. 78.
    Senzolo M, Cholongitas EC, Patch D, Burroughs AK. Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome. Nat Clin Pract Gastroenterol Hepatol. 2005;2:182–90.PubMedGoogle Scholar
  79. 79.
    Mancuso A, Fung K, Mela M, et al. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol. 2003;38:751–4.PubMedGoogle Scholar
  80. 80.
    Mancuso A, Watkinson A, Tibballs J, Patch D, Burroughs AK. Budd-Chiari syndrome with portal, splenic, and superior mesenteric vein thrombosis treated with TIPS: who dares wins. Gut. 2003;52:438.PubMedGoogle Scholar
  81. 81.
    Perello A, Garcia-Pagan JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology. 2002;35:132–9.PubMedGoogle Scholar
  82. 82.
    Hernandez-Guerra M, Turnes J, Rubinstein P, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology. 2004;40:1197–202.PubMedGoogle Scholar
  83. 83.
    Garcia-Pagan JC, Heydtmann M, Raffa S, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–15.PubMedGoogle Scholar
  84. 84.
    Slakey DP, Klein AS, Venbrux AC, Cameron JL. Budd-Chiari syndrome: current management options. Ann Surg. 2001;233:522–7.PubMedGoogle Scholar
  85. 85.
    Orloff MJ, Daily PO, Orloff SL, Girard B, Orloff MS. A 27-year experience with surgical treatment of Budd-Chiari syndrome. Ann Surg. 2000;232:340–52.PubMedGoogle Scholar
  86. 86.
    Ringe B, Lang H, Oldhafer KJ, et al. Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. Hepatology. 1995;21:1337–44.PubMedGoogle Scholar
  87. 87.
    Wang ZG, Jones RS. Budd-Chiari syndrome. Curr Probl Surg. 1996;33:83–211.PubMedGoogle Scholar
  88. 88.
    Klein AS, Cameron JL. Diagnosis and management of the Budd-Chiari syndrome. Am J Surg. 1990;160:128–33.PubMedGoogle Scholar
  89. 89.
    Chang CH, Lee MC, Shieh MJ, Chang JP, Lin PJ. Transatrial membranotomy for Budd-Chiari syndrome. Ann Thorac Surg. 1989;48:409–12.PubMedGoogle Scholar
  90. 90.
    Senning A. Transcaval posterocranial resection of the liver as treatment of the Budd-Chiari syndrome. World J Surg. 1983;7:632–40.PubMedGoogle Scholar
  91. 91.
    Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres. J Hepatol. 2006;44:520–8.PubMedGoogle Scholar
  92. 92.
    Segev DL, Nguyen GC, Locke JE, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl. 2007;13:1285–94.PubMedGoogle Scholar
  93. 93.
    Bras G, Jelliffe DB, Stuart KL. Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica. AMA Arch Pathol. 1954;57:285–300.PubMedGoogle Scholar
  94. 94.
    DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27–42.PubMedGoogle Scholar
  95. 95.
    Carreras E, Granena A, Navasa M, et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol. 1993;66:77–80.PubMedGoogle Scholar
  96. 96.
    Meresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant. 1992;10:135–41.PubMedGoogle Scholar
  97. 97.
    Ayash LJ, Hunt M, Antman K, et al. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990;8:1699–706.PubMedGoogle Scholar
  98. 98.
    DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology. 1999;29:1779–91.PubMedGoogle Scholar
  99. 99.
    Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol. 1987;127:549–58.PubMedGoogle Scholar
  100. 100.
    Sato Y, Asada Y, Hara S, et al. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology. 1999;34:66–70.PubMedGoogle Scholar
  101. 101.
    DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology. 1996;24:830–7.PubMedGoogle Scholar
  102. 102.
    DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology. 1996;23:589–99.PubMedGoogle Scholar
  103. 103.
    Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Klein J. Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity. Ann Pharmacother. 2004;38:1053–9.PubMedGoogle Scholar
  104. 104.
    Mertens R, Brost H, Granzen B, Nowak-Gottl U. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer. Eur J Pediatr. 1999;158 Suppl 3:S154–8.PubMedGoogle Scholar
  105. 105.
    Nimer SD, Milewicz AL, Champlin RE, Busuttil RW. Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation. Transplantation. 1990;49:819–21.PubMedGoogle Scholar
  106. 106.
    Kim ID, Egawa H, Marui Y, et al. A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation. Am J Transplant. 2002;2:796–800.PubMedGoogle Scholar
  107. 107.
    Rapoport AP, Doyle HR, Starzl T, Rowe JM, Doeblin T, DiPersio JF. Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant. 1991;8:421–4.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Internal Medicine, Gastroenterology SectionHacettepe UniversityAnkaraTurkey

Personalised recommendations